Equity research analysts tracking Emergent BioSolutions (EBS) generally view the stock with cautious or speculative ratings, balancing its deep value metrics and role as a critical biodefense supplier against recent operational challenges. While certain institutional analysts maintain buy ratings with target upside based on turnaround efforts, others point to high volatility, recent earnings impairments, and ongoing legal investigations, making thorough risk assessment vital.